Photo for representation
Bhubaneswar: National Technical Advisory Group on Immunization (NTAGI) has approved Serum Institute of India’s COVID-19 vaccine Covovax for the 12-17 age group, sources told news agency ANI on Friday.
Notably, an expert panel of the country’s central drug authority recommended granting emergency use authorisation (EUA) to Covovax for this age group subject to certain conditions, on March 9. Subsequently, the Pune-based firm started to pursue regulatory permissions and its protocol.
Covovax has been developed through a technology transfer protocol from Novavax, which already has approval from the European medicines agency for conditional marketing authorisation.
India began inoculating children aged 12-14 on March 16 with Biological E’s Corbevax.
Mumbai: Bollywood celebrities have often had funny, at times bizarre experiences, mostly involving hero-worshipping, demanding fans.…
Bhubaneswar: Police have arrested the owner of a Jatra (theatre) group for allegedly duping an…
Sanskriti Talwar Faridkot (Punjab): For the third consecutive year, Balwinder Singh of Mallan village in…
Bhubaneswar: Rain may play spoilsport in Christmas and New Year celebrations in Odisha as the…
New Delhi: Netflix showed the way, Amazon Prime Video is following in their footsteps. Come…
Hyderabad: Allu Arjun’s woes keep mounting. In a worrying development, protesters stormed Allu Arjun’s Jubilee…
This website uses cookies.